Gilead Sciences (GILD) : Iguana Healthcare Management reduced its stake in Gilead Sciences by 5.56% during the most recent quarter end. The investment management company now holds a total of 85,000 shares of Gilead Sciences which is valued at $6,771,100 after selling 5,000 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Gilead Sciences makes up approximately 2.67% of Iguana Healthcare Management’s portfolio.
Other Hedge Funds, Including , Sfmg reduced its stake in GILD by selling 75 shares or 0.71% in the most recent quarter. The Hedge Fund company now holds 10,449 shares of GILD which is valued at $832,367. Gilead Sciences makes up approx 0.18% of Sfmg’s portfolio. Bks Advisors added GILD to its portfolio by purchasing 2,958 company shares during the most recent quarter which is valued at $235,368. Gilead Sciences makes up approx 0.12% of Bks Advisors’s portfolio.Ncm Capital Management Group Inc reduced its stake in GILD by selling 50 shares or 3.04% in the most recent quarter. The Hedge Fund company now holds 1,597 shares of GILD which is valued at $128,415. Gilead Sciences makes up approx 1.53% of Ncm Capital Management Group Inc’s portfolio.Janney Montgomery Scott boosted its stake in GILD in the latest quarter, The investment management firm added 287,693 additional shares and now holds a total of 558,591 shares of Gilead Sciences which is valued at $44,916,302. Gilead Sciences makes up approx 0.68% of Janney Montgomery Scott’s portfolio.
Gilead Sciences opened for trading at $78.38 and hit $78.805 on the upside on Wednesday, eventually ending the session at $78.22, with a gain of 0.44% or 0.34 points. The heightened volatility saw the trading volume jump to 8,232,697 shares. Company has a market cap of $103,224 M.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Upgraded by Jefferies to ” Buy” on Sep 6, 2016. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.